Weight loss drug may benefit patients with peripheral artery disease, Type 2 diabetes

Semaglutide could be effective at improving outcomes among patients with peripheral artery disease and Type 2 diabetes.

In an international STRIDE trial published in The Lancet, researchers randomly assigned 792 adult patients with peripheral artery disease and Type 2 diabetes to receive a once-weekly injection of semaglutide or placebo.

After a follow-up of 52 weeks, the researchers found that the patients who received semaglutide experienced improvements in their maximum walking distance — as measured by a treadmill with a 12% incline — pain-free walking distance, physical function and quality of life compared with those who received placebo. The patients in the semaglutide group also demonstrated greater weight reduction, lower hemoglobin A1c levels and a reduced need for revascularization or new medical treatment.

The researchers suggested that semaglutide could provide an additional benefit among this patient population.

Read more: The Lancet

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.